Summit Therapeutics (SMMT) shares fell 16.5% to $11.82 on Monday, November 16, 2026, after the company said the Food and Drug Administration (FDA) issued a Complete Response Letter on its application to market ivonescimab in a form of lung cancer. The company said the letter indicates the application cannot be approved in its present form, as the FDA found that effectiveness was not established without a statistically significant improvement in overall survival.
What happened
Summit announced the letter in a press release dated Sunday, November 15. It filed the release with the SEC as an exhibit to a Form 8-K, and the SEC filing index shows the 8-K was accepted at 6:08 a.m. on November 16.
The application, a Biologics License Application (BLA), covered ivonescimab combined with platinum containing chemotherapy. It was for patients with locally advanced or metastatic non small cell lung cancer (NSCLC) who had received prior EGFR tyrosine kinase inhibitor therapy. It was supported by data from HARMONi, a global Phase III trial.
According to the release, HARMONi met its primary endpoint for progression free survival. In the primary analysis for overall survival, the combination showed a positive trend without achieving a statistically significant result. The company said the FDA indicated that a progression free survival benefit, without a statistically significant survival benefit, does not support a positive benefit risk profile.
Chairman Robert W. Duggan said in the release: "We are disappointed for patients and their families awaiting additional treatment options in this setting."
The numbers
- Close: $11.82, down 16.5% from $14.15 on November 13 (Nasdaq data)
- Overall survival hazard ratio: 0.76 in the full population, from a post hoc analysis with longer term follow up of western patients, according to the company (press release)
Context
The release says ivonescimab was invented by Akeso Inc. and was initially approved for marketing in China in May 2024. It is not approved by any regulatory authority in Summit's license territories, including the United States and Europe.
Summit said it is also running trials of ivonescimab in NSCLC, colorectal cancer, urothelial carcinoma and renal cell carcinoma.


